Registered & Corporate Office:
AMANTA HEALTHCARE LIMITED
8th Floor, Shaligram Corporates, CJ Marg,
Ambli, Ahmedabad–380058, Gujarat, INDIA.
Tel.: 079 – 67777600
Email: info@amanta.co.in
Website: www.amanta.co.in

CIN: L24139GJ1994PLC023944

November 4, 2026

To, Sr. General Manager Listing Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Scrip Code: **544502**	To, Sr. General Manager **National Stock Exchange of India Limited** Exchange Plaza, C-1, Block G Bandra Kurla Complex Bandra (E), Mumbai – 400 051. Trading Symbol: **AMANTA**

Dear Sir/ Madam,

Sub: Investors Presentation on Financial Results of the Company for the quarter and half year ended September 30, 2026

Please find enclosed the Investors Presentation on Financial Results of the Company for the quarter and half year ended September 30, 2026.

You are requested to take the same on your records.

Thanking you.

Yours sincerely,

For AMANTA HEALTHCARE LIMITED

Dinodia Nikhita

Digitally signed by Dinodia Nikhita
DN: c=IN, o=Personal, title=8566, pseudonym=2110201e1d024716bc7c8cb71aee2c6c, 2.5.4.20=de51f0a5a2bf09c322653af79eb52283df1d5f06355edec1ca4d84b91a1a643a, postalCode=380028, st=Gujarat, serialNumber=815d8bd656eb87ef922a9a611aad1a8cbaf1069644ddf48b498a62779ad541684, cn=Dinodia Nikhita
Date: 2026.11.04 11:35:33 +05'30'

NIKHITA DINODIA
COMPANY SECRETARY & COMPLIANCE OFFICER

Encl.: As above









Amanta Healthcare Limited

Q2 & H1 FY27 Investor Presentation

November, 2026

Disclaimer

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Amanta Healthcare Ltd.** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.



01

SECTION 01

Performance

Q2 & H1 FY27 Financial Highlights

The capacity-led growth phase begins



Strategic Highlights

Q2FY27 topline grows 17% with PAT growth of 26% YoY basis

01 Financial performance

- Q2 FY27 revenue ₹83.13 Cr, 17.3% YoY
- Q2 FY27 EBITDA ₹17.95 Cr; margin 21.6%, resulting in PAT of ₹4.86Cr with a margin of 6%
- H1 FY27 revenue ₹151.94 Cr; PAT ₹8.17 Cr.

02 SteriPort Line 3 is live

- Commissioned in the first week of September 2026 at the existing Kheda facility
- SteriPort capacity up 75%: 6.6 Cr → 11.6 Cr bottles
- ~₹60 Cr revenue expected in FY27; ₹110–120 Cr a year at optimal utilisation

03 SVP expansion next

- Capacity to rise from 20.9 Cr to 31.7 Cr units during Q1 of FY28.
- Adds inhalation, ophthalmics and diluents in the highest-margin segment (22–27% EBITDA)

04 Cost and balance sheet


- 10.8 MW captive solar generating since end-Q1 FY27; ~₹9 Cr annual power savings
- Debt-to-equity down from 3.5x (FY23) to ~1.1x (FY26)

Two-year aim: *Revenue CAGR* ***20%+*** | *EBITDA margin* ***25%+***


Financial Performance – Q2FY27

(Figures in INR Cr.)


Revenue




EBITDA and Margins (%)




PAT and Margins (%)




Revenue



EBITDA and Margins (%)



PAT and Margins (%)



Profit and Loss Statement

(Figures in Rs. crs)

Particulars	Q2FY27	Q2FY26	YoY	H1FY27	H1FY26	YOY
Revenues	83	71	17%	152	136	12%
Other Income	1	0	-	1	1	36%
Total Income	**84**	**71**	**18%**	**153**	**137**	**12%**
Cost of materials consumed	28	24	17%	50	48	6%
Purchases of stock-in-trade	1	2	-38%	4	5	-18%
Changes in inventories of finished goods, work-in-process and stock-in-trade	4	(2)	-	-1	-11	-
Employee costs	12	11	11%	23	21	12%
Other expenses	21	22	-5%	43	44	-2%
Total Expenditure	66	56	17%	120	107	13%
EBITDA	**18**	**15**	**22%**	**33**	**31**	**8%**
Finance Costs	6	5	13%	12	11	4%
Depreciation and Amortization Expenses	5	5	13%	10	9	7%
PBT before Exceptional Items	**7**	**5**	**39%**	**11**	**10**	**15%**
Exceptional Items	-	3	-	-	3	-
PBT	7	2	-	11	7	57%
Tax	2	1	84%	3	2	26%
PAT	**5**	**1**	**303%**	**8**	**5**	**73%**

Balance Sheet

(Figures in Rs. crs)

Assets	FY26	H1FY27
Non-Current Assets		
Property, plant and equipment	197	312
Capital work-in-progress	82	0
Right-of-use assets	9	8
Intangible assets	1	1
Non-Current Financial Assets	16	14
Non current tax assets(Net)	0	1
Other Non-Current Assets	15	15
Total Non-Current Assets	**320**	**352**
Current Assets		
Inventories	83	89
Trade receivables	43	44
Cash & Cash Equivalents	81	2
Bank Balance Other Than Cash	12	25
Other Financial Assets	0	0
Loans	1	0
Other Current Assets	19	16
Total Current Assets	**238**	**177**
Total Assets	**558**	**529**

Equities & Liabilities	FY26	H1FY27
Equity share capital	39	39
Other Equity	181	189
Net Worth	**220**	**228**
Non-Current Liabilities		
Non-Current Borrowings	162	49
Lease Liabilities	8	7
Deferred Tax Liabilities (Net)	27	29
Total Non-Current Liabilities	**197**	**85**
Current Liabilities		
Current Borrowings	72	147
Lease Liabilities	2	2
Current Tax Liabilities(Net)	3	3
Trade Payables	36	33
Provisions	11	12
Other Current Liabilities	1	1
Other Financial Liabilities	7	8
Contract Liabilities	9	8
Total Current Liabilities	**141**	**216**
Total Equity & Liabilities	**558**	**529**

Growth Levers

Amanta

Three pillars working together towards 20%+ revenue CAGR and 25%+ EBITDA margin

01 MARKET DEPTH

Wallet share expansion

- Complex dosages and niche molecules across anti-infectives, respiratory care and ophthalmics
- Deeper presence in advanced markets

PORTFOLIO **New sterile dosage forms**

02 MANUFACTURING

Capacity expansion

- SteriPort Line 3 live since Sep 2026: +5.0 Cr bottles
- SVP expansion: +10.8 Cr units during Q1 of FY28.

CAPACITY **+75% SteriPort · +52% SVP**

03 EFFICIENCY

Green energy & cost optimisation

- 10.8 MW captive solar; ~₹9 Cr expected annual saving
- Fixed-cost leverage: new lines share existing infrastructure, workforce and utilities

SAVINGS **~₹9 Cr a year**

MILESTONES

Q1 FY27 ✓
Captive solar commissioned

Sep 2026 ✓
SteriPort Line 3 commissioned

FY27
~₹60 Cr revenue from Line 3

Q1 FY28
SVP expansion operational

Within 12 months
Line 3 at full ramp-up

03

SECTION 04

Company Overview

Amanta at a Glance

IN THIS SECTION

- Business model
- Product portfolio
- Manufacturing & technology
- Exports
- Leadership



Amanta

NICHE PHARMACEUTICAL COMPANY

30+ Years of *Sterile Liquids* Legacy

Integrated
LVPs & SVPs manufacturer

SteriPort
Established generic brand

Widely used in hospitals
Critical medications

Advanced tech
ABFS & ISBM across 6 therapeutic segments

OPERATIONAL METRICS

47	7	1
Product portfolio	Production lines	WHO-GMP facility
320	120	506
Distributors & stockists	Intl. jurisdictions	Team size
30	21	6
Years in business	Countries exported	Therapeutic segments

FINANCIAL METRICS

REVENUE CAGR
11%
FY21–26

EBITDA CAGR
10%
FY21–26

ROE
8.9%
FY26

ROCE
11.1%
FY26

DEBT TO EQUITY
3.50× → 1.07×
FY23 to FY26 — improving

NET WORKING CAPITAL DAYS
141 days
FY26

IV Fluids | Diluents | Ophthalmic | Respiratory Care | Irrigation Solutions | Formulations


Built to scale – Amanta's differentiated business model

RM Sourcing

Key materials Sourced

27.5% LDPE	18.5% TWO PORT CLOSURE SYSTEM	12.5% POLYPROPYLENE

Geographical concentration of Plastic Purchase




Top 10 suppliers account for 76% of materials consumed

Manufacturing Capabilities

Manufacturing facility in Gujarat spanning 66,852 sq. mts

LVP 4 lines	SVP 3 lines
Total Capacity : 12.28 crore	Total Capacity : 20.91 crore
2 Lines : Conventional Single port bottles	2 Lines: ABFS
2 Lines : Steriport with ISBM technology	1 Line : Conventional 3-piece container



3 Channel Distribution

Robust sales and distribution team with strong presence across the globe

Branded products domestically through **320+** distributors

Exports to emerging and semi-regulated markets

Product Partnering

Portfolio expansion in markets such as UK, Latin America, South East Asia & Africa

Solutions : A Diverse Product Portfolio (1/2)








Types of IV Fluids :
Dextrose, Normal Saline, Combination Of Dextrose Normal Saline, Ringer Lactate, Electrolytes.

Packaging Of Product :
Single Port Container, Two Port Container

Fill Volume Options :
100ml, 250ml, 500ml, 1000ml.

Innovative Technology :
Amanta manufactures SteriPort bottles for IV fluids using ISBM Technology, with polypropylene as the raw material




Notable Formulations :
Ciprofloxacin, Metronidazole, Ofloxacin, Paracetamol, Fluconazole.

Packaging Options :
- Large Volume Parenterals (LVPs)
- Small Volume Parenterals (SVPs)

Fill Volume Range :
2ml to 100ml

Technology :
Aseptic Blow-Fill- Seal (ABFS) & Injection Stretch Blow Moulding (ISBM) technology




Revenue share across all categories

Diluent Product Overview :
- Plain Water for Injection (WFI)
- Normal Saline


Diluents Pack Sizes :
Offered in 5 ml & 10 ml

Injectables Portfolio Key Products :
Lidocaine, Potassium Chloride, Magnesium Sulphate, Calcium Chloride, Calcium Gluconate



Solutions : A Diverse Product Portfolio (2/2)







Applications :


Treatment for Infections, Glaucoma, Inflammation.

Dosage Forms :

5ml & 10 ml

Packaging Options :

- Form Fill Seal (FFS) Pack
- Three-Piece Conventional Pack



Applications :

Administered through nebulisers for the treatment of lungs affected by Asthma or Bronchiectasis

Dosage Form :

Available in 2.5 ml


Key Products :

Respiratory Suspension

Budesonide, Salbutamol

- Salbutamol & Ipratropium Bromide
- Levosalbutamol

Levosalbutamol & Ipratropium



Product Types :


OTC Eye Lubricants
Wound Cleaning Solutions

Dosage Forms :

Available in 5 ml, 10 ml & 20 ml

Product :

- Sodium Chloride Eye Wash
- Wound Cleaning



Core Competitive Advantages

Driving *Success*

47 Products

120 Countries

30+ Years



PRODUCTS & MARKETS

Well-established Pharma Manufacturer

Six therapeutic segments and container systems. 47 products registered in 120 countries across LVPs and SVPs.

47 Products

DISTRIBUTION

Wide Domestic & Global Network

Pan-India network of 320 distributors, 96 sales staff, and presence across 21 export markets.

320 Distributors

INFRASTRUCTURE

Scaled-up Manufacturing Capabilities

Gujarat facility spanning 66,852 sq. meters with Aseptic BFS and ISBM technologies. ISO & WHO-GMP certified.

66,852 sq.m

HUMAN CAPITAL

Leadership & Skilled Workforce

Management team with 30+ years of experience, supported by 506 employees (≈1,700 with contract workers).

506 Employees

Differentiated Manufacturing Technologies to Market End Product

First to bring ISBM technology to India

TECHNOLOGY 01

Aseptic Blow Fill Seal (ABFS)

Technology

FFS (Form-Fill-Seal) used for IV fluid packaging.

Process

Bottles formed, filled and sealed in one automated step — zero human contact.

Features

Nitrogen purging for sensitive formulations like paracetamol.

Capacity

Produces 8 bottles in ~15 seconds.

TECHNOLOGY 02

Injection Stretch-Blow Moulding (ISBM)

Technology

Multiple-stage operation using preforms, unlike FFS.

Process

Preforms stretched and blown into PP bottles from 100 ml upward.

Filling

Bottles air washed, WFI washed, dried, filled and sealed.

Advantage

50–60% domestic market share, commanding premium pricing.

SUPPORT SYSTEM

F&D Capability

In - house Product development

Dedicated team for Regulatory Affairs.

PIC complaint facility

Excellent Manufacturing Facilities

Location:
Block No: 872B, 873A, 874, 876 and 877 village Hariyala, District Kheda Gujarat, India

Certifications & Compliance:

- ISO 9001:2015, ISO 13485:2016, ISO 14001:2015, ISO 45001:2018, WHO-GMP certified.
- Certified by the Food & Drugs Control Administration Gujarat.
- Conformity with WHO guidelines and GMP for formulations from Cambodia, Sudan, Philippines, and Zimbabwe.

Production Capabilities:


- Injections
- Sterile Liquids
- Eye Care Products
- Respiratory Solutions



Sweating the assets to peak capacity

Amanta

Utilization % across each Parenteral




FY26	Installed capacity (Units in crs)
LVP (excluding SteriPort)	5.7
SVP	20.9
SteriPort	6.6

Current Utilization of 96% - indicating strong demand visibility and efficient asset utilization.

Stable installed capacity combined with rising actual production highlights the company's operational discipline


Capex to drive future growth





Capex & Robust product pipeline to drive future growth

- Capacity Scale-up across all the lines
- Transition to Renewable Energy / Solar Power Integration
- Accelerated Product Pipeline / New Product Rollouts

Increased Focus on exports – Driving higher margins









Sales focus	Domestic branded generics sold under proprietary brand names.
Distribution network	Approximately 320 distributors and stockist across India.
Sales and marketing team strength	Approximately 96 personnel
Geographic Expansion	Primarily into regulated markets.

Export markets	21 countries as of Fiscal 2025.
Product range	• LVP Pack Solutions: IV solutions, anti-fungal, and anti-protozoal formulations. • SVP Pack Solutions: SWFI (Sterile Water for Injection), ophthalmic, injections, and respiratory products.
Market focus	• Current Markets: Emerging and semi-regulated international markets. • Expansion Targets: Regulated markets including the UK, Zimbabwe, Sudan, Cambodia, Philippines, and Ethiopia.
Product registrations	Portfolio of 47 products registered across 120 international jurisdictions.
New product Offerings	Inhalation Solutions (Respules) / Ophthalmics.

De-leveraging in overdrive: Debt-to-Equity ratio reduced by over 70% since FY23

- Reduced total borrowings by over INR 30 Cr, primarily through the full repayment of all outstanding Non-Convertible Debentures (NCDs).





Leadership: The Board Of Directors



Mr. Bhavesh Patel
Chairman and Managing Director
30+ Years Of Experience



Mr. Pratik Gandhi
Non-Executive Director
10+ Years Of Experience



Mr. Nimesh Patel
Non-Executive Director
3+ Years Of Experience

Bhavesh Patel is the Chairman and Managing Director and a promoter of the Company, associated since its incorporation. With over 30 years of industry experience, he is a Mechanical Engineer and a graduate in Finance.

Pratik Gandhi is the Non-Executive Director of our Company. With over 10 years of teaching experience, he is a qualified cost and work accountant.

Nimesh Patel is the Non-Executive and Non-Independent Director of our company. He is a graduate of the Wharton School with a degree of Science in Economics.

Leadership: The Board Of Directors



Ms. Anjali Choksi
Independent Director
15+ Years Of Experience

Anjali Choksi is an Independent Director of the Company. She is a qualified chartered accountant & holds Ph.D in philosophy. Over 15 years of experience as a partner at DNV & Co. – CA firm.



Mr. Kshitij Patel
Independent Director
25+ Years Of Experience

Kshitij Patel is the Independent and Non-Executive Director of the company. A qualified chartered accountant & a partner of the firm Manubhai & Shah LLP.



Mr. Nitin Jain
Independent Director
20+ Years Of Experience

Nitin Jain is an Independent Director of our Company. Having over 20 yrs experience as an Investment Banker & a partner of the firm Fulcrum Advisors. He is a graduate in Chemical Engineering & Postgraduate in management from IIM – Bengaluru.

04

SECTION 02

Annual Performance

FY23 – FY26 Financials



Revenue Breakdown – Annual performance

(Figures in Rs. crs)

Revenue from operations	FY26	FY25	FY24	FY23
Revenue from contract with customers :				
Sale of products	282	267	272	253
Sale of services	3	5	6	5
Sub- total	**284**	**272**	**278**	**258**
Other operating revenue :				
Scrap sales	2	1	1	1
Export incentives	2	1	0	1
Total	**288**	**275**	**280**	**259**

Profit and Loss Statement

(Figures in Rs. crs)

Particulars	FY26	FY25	FY24	FY23
Revenues	288	275	280	259
Other Income	3	1	1	4
Total Income	**291**	**276**	**282**	**263**
Cost of materials consumed	97	101	86	101
Purchases of stock-in-trade	11	12	2	1
Changes in inventories of finished goods, work-in-process and stock-in-trade	(11)	(20)	17	53
Employee costs	43	36	33	32
Other expenses	88	85	85	73
Total Expenditure	228	215	223	206
EBITDA	**63**	**61**	**59**	**56**
Finance Costs	21	28	34	35
Depreciation and Amortization Expenses	19	18	20	18
Exceptional Items	3	-	-	-
PBT	21	15	5	3
Tax	6	4	2	5
PAT	**15**	**11**	**4**	**(2)**
Restated Other Comprehensive Income/(loss) for the period, net of tax	1	0	0	0
Restated Total Comprehensive Income/(loss) for the period	14	10	3	(2)

Balance Sheet

(Figures in Rs. crs)

Assets	FY26	FY25	FY24	FY23
Non-Current Assets				
Property, plant and equipment	197	208	223	229
Capital work-in-progress	82	7	-	-
Right-of-use assets	9	9	5	9
Intangible assets	1	1	-	-
Non-Current Financial Assets	16	9	5	5
Non current tax assets(Net)	0	0	-	-
Other Non-Current Assets	15	11	1	0
Total Non-Current Assets	**320**	**244**	**234**	**243**
Current Assets				
Inventories	83	73	60	69
Trade receivables	43	50	48	54
Cash & Cash Equivalents	81	0	2	0
Bank Balance Other Than Cash	12	3	3	4
Other Financial Assets	0	-	-	-
Loans	1	1	0	0
Other Current Assets	19	11	6	5
Total Current Assets	**238**	**138**	**118**	**131**
Total Assets	**558**	**382**	**352**	**374**

Equities & Liabilities	FY26	FY25	FY24	FY23
Equity share capital	39	29	27	27
Other Equity	181	68	40	36
Net Worth	**220**	**96**	**66**	**63**
Non-Current Liabilities				
Non-Current Borrowings	162	132	149	176
Lease Liabilities	8	8	5	7
Deferred Tax Liabilities (Net)	27	30	30	32
Total Non-Current Liabilities	**197**	**170**	**184**	**214**
Current Liabilities				
Current Borrowings	72	63	56	40
Lease Liabilities	2	1	-	3
Current Tax Liabilities(Net)	3	1	1	3
Trade Payables	36	31	25	36
Provisions	11	8	7	6
Other Current Liabilities	1	2	2	1
Other Financial Liabilities	7	4	3	3
Contract Liabilities	9	6	8	6
Total Current Liabilities	**141**	**115**	**102**	**97**
Total Equity & Liabilities	**558**	**382**	**352**	**374**

Cash Flow Statement

(Figures in Rs. crs)

Particulars	FY26	FY25	FY24	FY23
Cashflow from Operating Activities	48	47	58	43
Cashflow from Investing Activities	(94)	(25)	(10)	(7)
Cashflow from Financing Activities	126	(24)	(46)	(42)
Cash and Cash Equivalents as at end of period/Year	**81**	**0.2**	**1.5**	**0.1**

05


SECTION 05

Annexure

Our Product Categories

IN THIS SECTION

IV fluids | Formulations | Diluents & injectables | Ophthalmic
Respiratory | Irrigation | Glossary



Amanta

Fluid Therapy - (IV Fluid)



Types of IV Fluids :

- Dextrose
- Normal Saline
- Combination Of Dextrose Normal Saline
- Ringer Lactate
- Electrolytes

Packaging Of Product :

- Single Port container
- Two Port container

Fill Volume Options :

- 100ml
- 250ml
- 500ml
- 1000ml

Innovative Technology :

- SteriPort bottles for IV fluid are manufactured with ISBM Technology using polypropylene as raw material

Formulations

Therapeutic Segments	Products
Anti - fungal	Fluconazole
Anti – Pyretic	Paracetamol
Diuretics	Mannitol IV
Anti - Biotic	Linezolid
Quinolones	Ciprofloxacin, Levofloxacin, Gemifloxacin and Moxifloxacin
Anti - Anaerobic	Metronidazole Tinidazole

Amanta

Product Focus :

- Injectables
- Ophthalmic
- Respiratory

Fill Volume Range :

- 2ml to 100ml

Technology :


- Aseptic Blow-Fill- Seal (ABFS) & Injection Stretch Blow Moulding (ISBM) technology

Notable Formulations:

- Ciprofloxacin
- Metronidazole
- Ofloxacin
- Paracetamol
- Fluconazole

Packaging Options:

- Large Volume Parenterals (LVPs)
- Small Volume Parenterals (SVPs)



Diluents & Injectables

Key Products :

- Lidocaine
- Potassium Chloride
- Magnesium Sulphate
- Calcium Chloride
- Calcium Gluconate

Injectables Portfolio





Diluents Overview

Pack Sizes :

- Offered in 5 ml & 10ml

Products :

- Sterile Water for Injection (WFI)
- Normal Saline WFI

Ophthalmic

Therapeutic segments	Product
Ophthalmic (FFS)	Ciprofloxacin Ophthalmic Solution U.S.P. (0.3 % w/v)
Ophthalmic (FFS)	Timolol Maleate Eye Drops B.P. (0.5 % w/v & 0.25 % w/v)
Ophthalmic (FFS)	Gentamicin Eye Drops B.P. (0.3% w/v)
Ophthalmic (FFS)	Gentamicin Sulphate (0.3 % base) & Dexamethasone (0.1% w/v) Eye/Ear Drops
Ophthalmic (FFS)	Tobramycin (0.3% w/v) + Dexamethasone (0.1% w/v) Eye Drops
Ophthalmic (3 Piece)	Carboxymethyl Cellulose Sodium Eye Drops (0.5 % w/v)
Ophthalmic (3 Piece)	Hypromellose Eye Drops (0.5v% w/v)
Ophthalmic (3 Piece)	Sodium Hyaluronate 0.3% w/v Eye Drops

Amanta

Dosage Form :

- 5ml & 10ml

Applications :

- Including treatment for Infections, Glaucoma, Inflammation

Package Options :

- Form Fill Seal (FFS) Pack
- Three-Piece Conventional Pack



Respiratory Solutions



Dosage Form :

- Available in 2.5ml

Applications :

- Administered through nebulizers for the treatment of lungs affected by Asthma or Bronchiectasis.

Key Product :

- Budesonide Respiratory Suspension
- Salbutamol Respiratory Solution
- Salbutamol & Ipratropium Bromide Respiratory Solution
- Levosalbutamol Inhalation solution
- Levosalbutamol and Ipratropium Respiratory Solution

Irrigation Solutions



Product Types :

- OTC Eye Lubricants
- Wound Cleaning Solutions

Dosage Forms :

- Available in 5ml, 10 ml & 20 ml

Product :

- Sodium Chloride Eye Wash
- Wound Cleaning

Glossary

LVP: Large Volume Parenteral

SVP: Small Volume Parenteral

ABFS: Aseptic Blow Fill Seal

ISBM: Injection Stretch-Blow Moulding

WFI: Water For Injection

SWFI: Sterile Water For Injection

WHO-GMP: WHO - Good Manufacturing Practices

PICs: Pharmaceutical Inspection Co-operation Scheme

ISO: International Organization for Standardization

SAL: Sterility Assurance Level

OTC: Over-the-Counter

ESG: Environmental, Social, and Governance



Amanta

Amanta Healthcare Ltd.
8th Floor, Shaligram Corporates,
C. J. Marg, Ambli, Ahmedabad 380058 Gujarat, India.
Telephone: 079 6777 7600
Email Id: cs@amanta.co.in
Website: www.amanta.co.in

Investor Relations
Go India Advisors

Name: Ms. Soumya Chhajed
Tel: +91-8619707750
Email:soumya@goindiaadvisors.com

Name: Mr. Bobby Ninan
Tel: +91-9004745782
Email: bobby@goindiaadvisors.com